Quantity of Opioids Prescribed Postop Linked to Consumption
THURSDAY, Nov. 8, 2018 -- The quantity of opioids prescribed after surgery is associated with patient-reported opioid consumption, according to a study published online Nov. 7 in JAMA Surgery.
Ryan Howard, M.D., from the University of Michigan in Ann Arbor, and colleagues conducted a retrospective, population-based analysis of opioids prescribed and consumed across 33 health systems in Michigan. A total of 2,392 patients who underwent one of 12 surgical procedures were included in the analysis.
The researchers found that the quantity of opioids prescribed was significantly higher than the quantity of those consumed (median, 30 pills of hydrocodone/acetaminophen versus nine pills). The strongest association for patient-reported opioid consumption was seen for the quantity of opioids prescribed; for every additional pill prescribed, patients used 0.53 more pills. There was also a significant, but smaller, correlation between patient-reported pain in the week after surgery and consumption. Patients used a mean of nine and 16 more pills if they reported moderate and severe pain, respectively, versus no pain. History of tobacco use, American Society of Anesthesiologists class, age, procedure type, and inpatient surgery status were also significant risk factors. Patients in the lowest versus the highest quintile of opioid prescribing had significantly lower mean opioid consumption (five versus 37 pills) after adjustment for these risk factors.
"Recognizing overprescribing and accurately identifying patient consumption after surgery is the first step in improving prescribing practices," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: November 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.